Zacks Research Issues Positive Estimate for HALO Earnings

Key Points

• Zacks Research raised its Q2 2026 earnings estimate for Halozyme Therapeutics to $1.24 per share, indicating a positive outlook for the biopharmaceutical company.
• Despite Zacks' positive rating, some brokerages have downgraded Halozyme, with a consensus rating of "Hold" and an average target price of $67.11.
• CEO Helen Torley sold 20,000 shares of Halozyme stock, highlighting insider trading activity amid mixed analyst sentiments.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Research analysts at Zacks Research upped their Q2 2026 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Monday, September 1st. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $1.24 per share for the quarter, up from their previous estimate of $1.20. Zacks Research currently has a "Strong-Buy" rating on the stock. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share.

A number of other brokerages have also commented on HALO. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They set a "neutral" rating and a $55.00 price target for the company. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a report on Tuesday, May 13th. Finally, HC Wainwright upped their price target on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Hold" and an average target price of $67.11.

Halozyme Therapeutics Stock Up 2.0%

HALO opened at $74.82 on Thursday. The business has a 50 day moving average price of $61.93 and a 200 day moving average price of $59.59. Halozyme Therapeutics has a twelve month low of $42.01 and a twelve month high of $74.94. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a market cap of $8.75 billion, a P/E ratio of 17.12, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. During the same period in the previous year, the company earned $0.91 EPS. The company's revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bernadette Connaughton sold 4,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $73.68, for a total value of $294,720.00. Following the sale, the director owned 46,952 shares in the company, valued at $3,459,423.36. The trade was a 7.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 84,000 shares of company stock worth $4,827,320 over the last quarter. Company insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several large investors have recently made changes to their positions in the company. Penserra Capital Management LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter worth about $125,000. Bessemer Group Inc. lifted its position in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of Halozyme Therapeutics by 171.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the last quarter. Fifth Third Bancorp lifted its position in shares of Halozyme Therapeutics by 29.4% in the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after buying an additional 2,276 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Halozyme Therapeutics by 199.0% in the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 1,865 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.